...
首页> 外文期刊>European review for medical and pharmacological sciences. >Overexpression of lncRNA MNX1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer
【24h】

Overexpression of lncRNA MNX1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer

机译:lncRNA MNX1-AS1的过度表达与上皮性卵巢癌的临床预后不良相关

获取原文
           

摘要

OBJECTIVE: Long non-coding RNAs MNX1-AS1(MNX1-AS1) has been proved to be associated with ovarian cancer proliferation and invasion. However, the clinical significance of MNX1-AS1 in epithelial ovarian cancer (EOC) patients remains unknown. The aim of this study was to investigate the prognostic value of the MNX1-AS1 expression in EOC. PATIENTS AND METHODS: We first measured MNX1-AS1 expression level in 177 paired of EOC and matched normal tissues by Real-time quantitative RT-PCR. The relevance of MNX1-AS1 expression to the clinicopathological factors was assessed. Overall survival (OS) and relapse-free survival (RFS) were analyzed by log-rank test, and survival curves were plotted according to Kaplan-Meier. Univariate and multivariate analyses were performed to analyze the prognostic significance of MNX1-AS1 expression. RESULTS: We found that the levels of MNX1-AS1 were higher in EOC tissue than in matched normal tissues (p<0.01). In addition, MNX1-AS1 expression level was significantly positively correlated with FIGO stage (p=0.005), grade (p=0.040) and distant metastasis (p=0.000). Kaplan-Meier survival curves demonstrated that patients with high-MNX1-AS1 expression showed poorer progression-free survival and overall survival than those with low-MNX1-AS1 expression (p<0.0001 and 0.0003, respectively). Then, Cox regression analysis revealed that FIGO stage, distant metastasis, and MNX1-AS1 expression were independent prognostic factors of both overall survival and progression-free survival for patients with EOC. CONCLUSIONS: Our findings indicated, for the first time, that MNX1-AS1 expression may be a useful marker for predicting the outcome in patients with EOC.
机译:目的:长非编码RNA MNX1-AS1(MNX1-AS1)已被证明与卵巢癌的增殖和侵袭有关。但是,MNX1-AS1在上皮性卵巢癌(EOC)患者中的临床意义仍然未知。这项研究的目的是调查ENX中MNX1-AS1表达的预后价值。患者和方法:我们首先通过实时定量RT-PCR测量了177对EOC和匹配的正常组织中MNX1-AS1的表达水平。评估了MNX1-AS1表达与临床病理因素的相关性。通过对数秩检验分析总生存期(OS)和无复发生存期(RFS),并根据Kaplan-Meier绘制生存曲线。进行单因素和多因素分析以分析MNX1-AS1表达的预后意义。结果:我们发现EOC组织中MNX1-AS1的水平高于匹配的正常组织(p <0.01)。另外,MNX1-AS1表达水平与FIGO分期(p = 0.005),等级(p = 0.040)和远处转移(p = 0.000)显着正相关。 Kaplan-Meier生存曲线表明,MNX1-AS1高表达的患者与MNX1-AS1低表达的患者相比,无进展生存期和总生存期差(分别为p <0.0001和0.0003)。然后,Cox回归分析显示FIGO分期,远处转移和MNX1-AS1表达是EOC患者总体生存和无进展生存的独立预后因素。结论:我们的发现首次表明MNX1-AS1表达可能是预测EOC患者预后的有用标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号